FINWIRES · TerminalLIVE
FINWIRES

BMO Capital Initiates Ascendis Pharma at Outperform

By

Ascendis Pharma A/S (ASND) has an average rating of buy and mean price target of $310.61, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

Related Articles